Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Preferentially Expressed Antigen in Melanoma
- Molecular classification
- Leucine-rich repeat protein, Cancer/testis antigen
01
Overview
Preferentially Expressed Antigen in Melanoma (PRAME) is a cancer/testis antigen highly expressed in various cancers, including melanoma and leukemia, but minimally expressed in normal adult tissues (except testis). It functions as a corepressor of retinoic acid receptor signaling, inhibiting differentiation and apoptosis. PRAME is an attractive target for cancer immunotherapy due to its restricted expression pattern and immunogenicity, and it also has diagnostic utility in distinguishing malignant melanoma from benign nevi.
- Other names
- PRAME
02
Mechanism of action
PRAME is targeted by immunotherapies (peptide vaccines, adoptive T-cell therapies) that stimulate cytotoxic T lymphocytes to recognize and kill PRAME-expressing cells.
03
Biological functions
Corepressor of retinoic acid receptor signalingInhibits cell differentiationInhibits apoptosisPromotes motility/invasivenessImmune target
04
Disease associations
Cancer
05
Safety considerations
Potential for off-target effects of immunotherapies
06
Biomarkers
PRAME expression levels in tumor tissue
Beyond the preview
Go deeper on Preferentially Expressed Antigen in Melanoma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Preferentially Expressed Antigen in Melanoma.